Semaglutide-Associated Ischemic Colitis in a Patient Without Traditional Risk Factors: A Case Report.
Cureus · 2025
Last updated 2026-08-28| Journal | Cureus, 2025 |
|---|---|
| Citations | 1 |
| Molecules | semaglutide |
Abstract
This report describes the case of a 43-year-old female patient presenting with left lower quadrant pain and bloody diarrhea, initially managed as infectious colitis. Despite treatment, symptoms persisted, leading to repeat imaging showing mild pancolitis with colon mucosal hyperenhancement and wall thickening. Admission for intravenous hydration and subsequent colonoscopy revealed findings consistent with ischemic colitis. Semaglutide (Ozempic), which the patient had been taking, was discontinued, and symptoms resolved post discharge without semaglutide use for several months. This suggests a potential association between semaglutide and ischemic colitis in a patient without known risk factors. This case underscores the importance of considering medication-induced colitis in patients presenting with persistent gastrointestinal symptoms, particularly in the absence of typical risk factors.
Verbatim abstract via PubMed 40084311 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.